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Background
IPI (Yervoy®, Bristol-Myers Squibb) blocks cytotoxic T-
lymphocyte antigen-4, a regulatory molecule on activated
T cells. In March 2011, IPI, indicated for unresectable or
metastatic melanoma (MEL), became the first immune
checkpoint inhibitor approved by the US Food and Drug
Administration (FDA). Early in development, severe and
fatal immune-related adverse events (irAEs) emerged and
were attributed to IPI’s mechanism of action, occurring
mostly during treatment, although a minority occurred
weeks to months after drug discontinuation. irAE manage-
ment guidelines created in collaboration with external
experts and study investigators were progressively incor-
porated into the IPI Investigator’s Brochure.
Methods
At approval, the FDA stipulated that a Risk Evaluation and
Mitigation Strategy (REMS) communication plan directed
at healthcare providers (HCPs) be developed to ensure
that benefits with IPI outweighed irAE risks. The REMS
goal was to inform HCPs about serious risks with IPI and
irAE management. Multichannel educational outreach to
HCPs was implemented at launch and every 6 months for
3 years, in addition to a dedicated webpage and triggered
outreach to new prescribers. REMS materials included a
Dear HCP Letter, management guide, nursing checklist,
and patient (pt) wallet card. Audience was HCPs who
manage pts with MEL (eg, oncologists) and HCPs who
may be consulted about irAEs (eg, gastroenterologists).
Professional medical societies were also contacted to
inform their memberships.
Results
During the 3-year outreach effort, REMS materials were
distributed via >160,000–250,000 emails per outreach
and >700,000 total mailings. Prescriber understanding of
irAE management was assessed twice, via oncologist
knowledge surveys, with median correct scores of 76%
in 2012 and 85% in 2014. Academic and community
HCPs tested equally well. Pharmacovigilance review of
fatal irAEs showed no delay in recognizing and treating
irAEs, and management was consistent with US pre-
scribing information. Periodic, aggregate safety data did
not identify any new safety concerns. Because the REMS
met its goal and key activities were successfully com-
pleted with no required modifications at the 18-month
and the 3-year assessments, the FDA released the REMS
in March 2015. Voluntary IPI safety education efforts
continue worldwide.
Conclusions
Management algorithms and safety education materials
were created through early collaboration with investiga-
tors and then broadly disseminated through the IPI
REMS, increasing HCP awareness of irAE management.
Socialization of irAE identification and management
through the sentinel IPI safety education experience has
benefited newer immuno-oncology agents, and IPI safety
materials remain highly regarded and utilized by HCPs.
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